NovoCure二季度收入创新高并上调2026年收入与调整后EBITDA指引

Earnings Call Insights: NovoCure (NVCR) Q2 2026
Management view
- “This was our strongest commercial quarter to date. With record net revenues and active patients on therapy, we continue to build on the momentum of the first quarter and have also made meaningful progress on our path to profitability.” (Executive Chairman William Doyle)
- “Starting with Optune Gio, we finished the quarter with 4,636 active patients on therapy, an increase of 11% year-over-year.” (Executive Chairman Doyle) “A key driver this quarter was U.S. growth, where active patients increased 8% year-over-year.” (Executive Chairman Doyle)
- “We received 418 prescriptions in the quarter and 285 Optune Pax patients were on therapy as of June 30.” (Executive Chairman Doyle) “We are encouraged by the adoption of Optune Pax at both academic and community practices.” (Executive Chairman Doyle)
- “Earlier this month, we received CE Mark for Optune Pax… concomitant with gemcitabine and nab-paclitaxel in accordance with local guidelines.” (Executive Chairman Doyle) “We have since finalized labeling and registration in Germany and begun certifying prescribers.” (Executive Chairman Doyle)
- “Turning to Optune Lua. We finished the period with 207 patients on therapy.” (Executive Chairman Doyle) “As of June 30, we had 64 Optune Lua patients on therapy in Japan.” (Executive Chairman Doyle)
- “The FDA review of Optune Maia… remains on track for a Q4 decision.” (Executive Chairman Doyle) “Earlier this month, the NCCN updated guidelines… and included Optune Maia as a Category 2A recommended treatment option…” (Executive Chairman Doyle)
- “With 3 products approved and under FDA review, we are shifting that mandate to focus on strengthening our market position and broadening labels.” (CEO Frank Leonard) “Our near-term focus is pancreatic cancer.” (CEO Leonard)
- “We believe these changes will cut the total spend on LUNAR by approximately $90 million with the savings allocated to pancreatic cancer programs.” (CEO Leonard)
- “Net revenue in the second quarter was $184 million, an increase of 16% year-over-year.” (Chief Financial Officer Christoph Brackmann) “We are updating our full year revenue guidance to a range of $710 million to $725 million…” (CFO Brackmann)
Outlook
- “Based on the strength of our commercial performance in Q2, we are updating our full year revenue guidance to a range of $710 million to $725 million, representing 8% to 11% growth.” (CFO Brackmann)
- “We are also updating our guidance range for combined revenue from Optune Lua and Optune Pax to $20 million to $30 million for the year.” (CFO Brackmann)
- “We are updating our full year adjusted EBITDA guidance this morning to a range from $0 million to $15 million.” (CFO Brackmann) “The first milestone in our path to profitability is to reach breakeven on an adjusted EBITDA level, which we now plan to achieve for the full year of 2026.” (CFO Brackmann)
- Compared with Q1 2026 guidance language, management moved from “a range from negative $15 million to breakeven” (CFO Brackmann) to “a range from $0 million to $15 million” (CFO Brackmann), and from “$690 million to $710 million” (CFO Brackmann) to “$710 million to $725 million” (CFO Brackmann).
Financial results
- “Gross margin in the quarter was 78% compared to 74% in Q2 of 2025.” (CFO Brackmann) “This was primarily due to a tariff refund of $5 million as well as lower array costs due to improved utilization and manufacturing efficiencies.” (CFO Brackmann)
- “We expect quarterly gross margins to remain in the mid-70s through year-end 2026 as we bring more Optune Pax patients on therapy prior to establishing broad reimbursement.” (CFO Brackmann)
- “Research and development costs in the quarter were $51 million…” (CFO Brackmann) “Sales and marketing expenses in Q2 were $62 million…” (CFO Brackmann) “G&A costs in the quarter were $40 million…” (CFO Brackmann)
- “Our net loss for the quarter was $16 million…” (CFO Brackmann) “Loss per share in the quarter was $0.13.” (CFO Brackmann) “Adjusted EBITDA in the quarter was $11 million…” (CFO Brackmann)
- “Our cash and investment balance as of June 30, 2026, was $441 million.” (CFO Brackmann)
Q&A
- Vijay Kumar, Evercore ISI: asked whether Optune Pax’s Q2 trajectory is sustainable and where growth is coming from; CEO Leonard said, “we are pleased with the launch,” and added, “we are right now looking at about half of our prescriber base has already become a repeat prescriber,” with a Q3 focus to “push that number of repeat prescribers up.” (CEO Leonard)
- Vijay Kumar, Evercore ISI: asked why an IDE trial with RAS inhibitors and whether a registrational study is needed; CEO Leonard said, “The fastest way… is… through an IDE trial,” adding, “we are opening this trial in order to look at safety and feasibility,” and “We are not in metastatic disease looking to move towards a registrational trial…” (CEO Leonard)
- Jason Bednar, Piper Sandler: asked about Rx-to-active conversion and whether Pax fill rates differ from Gio; CEO Leonard said, “I wouldn't begin trying to glean specific statistics from the numbers,” and added, “it's a shorter time between prescription and start than what we typically see in GBM.” (CEO Leonard)
- Jason Bednar, Piper Sandler: questioned why the updated revenue guide implies moderation; CFO Brackmann cited “$3 million in onetime items” and said “the stars aligned in Q2,” adding, “we also wanted to respect that we had a fantastic quarter in Q2.” (CFO Brackmann)
- Larry Biegelsen, Wells Fargo: asked about Lua demand and second-half outlook; CFO Brackmann said, “We are very pleased with the launch,” and flagged contracting as “a gating item” despite “national reimbursement.” (CFO Brackmann)
- Jessica Fye, JPMorgan: pressed for total Optune Pax prescribers; CEO Leonard said, “We haven't given the specific number of certified prescribers,” and described a range where “some doctors have written more than 10 prescriptions.” (CEO Leonard)
- Kevin DeGeeter, Ladenburg Thalmann: asked about Germany go-to-market and reimbursement; CEO Leonard said Germany allows “case-by-case reimbursement,” and CFO Brackmann sized the on-label opportunity: “The TAM in the U.S. on label is 15,000 patients annually… And in Germany… 4,000 patients on label.” (CFO Brackmann)
Sentiment analysis
- Analysts’ tone was slightly positive, with repeated launch-focused probing; examples included “Script volumes up sequentially in the triple digits… Is this sustainable… for back half?” (Vijay Kumar, Evercore ISI) and “what's the total number of prescribers… sourcing those 418 Pax scripts” (Jessica Fye, JPMorgan).
- Management’s tone was positive and execution-focused in prepared remarks, including “we are updating our full year revenue guidance” (CFO Brackmann) and “we are shifting… to focus on strengthening our market position and broadening labels” (CEO Leonard), while staying measured in Q&A with lines such as “we are not giving context right now on the total number of certifications” (CEO Leonard).
- Compared with Q1, Q2 included more explicit profitability framing and cost actions, including “we believe these changes will cut the total spend on LUNAR by approximately $90 million” (CEO Leonard) and “we now plan to achieve [breakeven] for the full year of 2026” (CFO Brackmann).
Quarter-over-quarter comparison
- Strategy emphasis shifted from awaiting GBM catalyst TRIDENT (“top line data… expected in the second quarter” (CEO Leonard, Q1)) to reallocating lung trial resources and dollars, with Q2 detailing “reallocating clinical resources… discontinuing the trial at lower enrollment sites” and aiming to “reduce the patient sample size.” (CEO Leonard)
- Optune Pax launch discussion evolved from early funnel metrics in Q1 (“we certified 868 health care providers… received 169 prescriptions… completed 90 patient starts” (Executive Chairman Doyle, Q1)) to repeat-prescriber dynamics in Q2 (“about half of our prescriber base has already become a repeat prescriber” (CEO Leonard)).
- Guidance language moved higher in Q2, with management stating “updating our full year revenue guidance” (CFO Brackmann) and “updating our full year adjusted EBITDA guidance” (CFO Brackmann) versus Q1’s lower ranges. (CFO Brackmann)
Risks and concerns
- Reimbursement and contracting remained a near-term constraint outside the U.S., with management noting Japan requires “additional contracting… at each treatment site” (Executive Chairman Doyle) and describing contracting as “a gating item.” (CFO Brackmann)
- Gross margin variability was tied to launch and reimbursement timing, as CFO Brackmann said margins should stay “in the mid-70s… as we bring more Optune Pax patients on therapy prior to establishing broad reimbursement.” (CFO Brackmann)
- Clinical execution and cost control were framed as mitigations, including “operating expense discipline” (CEO Leonard) and “cost optimizing projects like the LUNAR-2 trial.” (CFO Brackmann)
Final takeaway
NovoCure’s management described Q2 as its “strongest commercial quarter to date” (Executive Chairman Doyle) and raised full-year revenue and adjusted EBITDA guidance while tying profitability goals to expense discipline and a reallocation of clinical spend—most notably, a LUNAR-2 redesign expected to reduce total trial spend by “approximately $90 million” (CEO Leonard) and fund expanded pancreatic cancer studies and combinations, alongside continued execution on Optune Pax uptake, Japan’s Optune Lua rollout, and a “Q4 decision” timeline for Optune Maia. (Executive Chairman Doyle)
Read the full Earnings Call Transcript